8-K: Kyverna Therapeutics Announces Positive Progress in Autoimmune Disease Therapies and Reports Q1 2025 Financial Results

Kyverna Therapeutics reports progress in clinical trials for KYV-101 in stiff person syndrome and myasthenia gravis, anticipates BLA filing in 1H 2026, and has a cash runway into 2027.

Summary

• Kyverna Therapeutics reported its Q1 2025 financial results and provided a business update.
• Enrollment is complete in the registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS), with topline data expected in the first half of 2026 and a biologics license application (BLA) filing anticipated in the same period.
• The company is advancing into a registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following a successful meeting with the FDA, with Phase 2 MG data expected in the second half of 2025.
• Kyverna plans to host a KOL event in Q3 2025 to highlight its neuroinflammation franchise.
• The company's cash runway extends into 2027, supporting the first BLA filing, the MG Phase 3 trial, and pre-launch activities.
• Cash, cash equivalents, and available-for-sale marketable securities totaled $242.6 million as of March 31, 2025.
• Research and Development (R&D) expenses were $37.4 million for the quarter ended March 31, 2025.
• General and Administrative (G&A) expenses were $10.0 million for the quarter ended March 31, 2025.
• The company reported a net loss of $44.6 million, or $1.03 per share, for the quarter ended March 31, 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and a strong cash position. However, the net loss and workforce reduction temper the overall sentiment.

Positives

• Kyverna has completed enrollment in the registrational Phase 2 trial for SPS.
• The company has aligned with the FDA on the registrational pathway for SPS and MG.
• Kyverna has a strong financial position with a cash runway into 2027.
• The company is advancing KYV-101 into a Phase 3 clinical trial for MG.
• Kyverna is exploring additional opportunities for KYV-101 in other autoimmune diseases.
• The FDA confirmed the company's planned CMC package to support commercial manufacturing of KYV-101 for SPS and MG.
• Kyverna successfully initiated clinical manufacturing at Elevate Bio.

Negatives

• Kyverna reported a net loss of $44.6 million for the quarter ended March 31, 2025.
• The company implemented a workforce reduction of approximately 16% in the first quarter of 2025.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties, including those related to market conditions, regulatory approvals, and intellectual property rights.
• The FDA or other regulatory agencies may require additional trials or studies to support the intended BLA submission.

Future Outlook

Kyverna anticipates filing its first BLA in the first half of 2026 and expects its cash runway to extend into 2027, supporting its first BLA filing, MG Phase 3 trial, and pre-launch activities.

Management Comments

• We are pleased to report an exceptional start to the year, marked by rapid execution against our focused strategy to advance development of KYV-101 and build Kyverna into a robust clinical and commercial-ready organization, said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.
• Importantly, we have now aligned with the FDA on the registrational pathway for our two lead indications, SPS and MG, laying the foundation for accelerating our potential first-in-class neuroinflammation franchise.
• Having recently completed enrollment in KYSA-8, our registrational study in SPS, we now anticipate filing our first BLA in the first half of 2026 and are strategically investing in pre-launch activities.
• We are working with a sense of urgency given SPS is a debilitating and progressive disease with no currently approved therapies.

Industry Context

Kyverna is focused on developing cell therapies for autoimmune diseases, a growing area of interest in the biopharmaceutical industry. The company's focus on neuroinflammation and its lead CAR T-cell therapy candidate, KYV-101, position it to potentially address unmet needs in diseases like stiff person syndrome and myasthenia gravis.

Comparison to Industry Standards

• Kyverna's approach to CAR T-cell therapy for autoimmune diseases aligns with the broader industry trend of exploring cell therapies beyond oncology.
• Companies like Bristol Myers Squibb and Johnson & Johnson are also investing in CAR T-cell therapies, primarily for cancer treatment, but the technology is being adapted for autoimmune conditions.
• Kyverna's focus on fully human CD19 CAR T-cells with CD28 co-stimulation is designed for tolerability, which is a key consideration in autoimmune diseases where minimizing immune-related side effects is crucial.
• The company's collaboration with Elevate Bio for manufacturing is a common strategy in the biotech industry to leverage specialized expertise and infrastructure.

Stakeholder Impact

• Shareholders: The progress in clinical trials and strong cash position are positive for shareholders.
• Employees: The workforce reduction of 16% has a negative impact on affected employees.
• Patients: The development of new therapies for autoimmune diseases has a positive impact on patients.

Next Steps

• Report interim Phase 2 data for Myasthenia Gravis (MG) in 2H 2025.
• Report Phase 1 data for Lupus Nephritis (LN) in 2H 2025.
• File KYV-102 IND application in 2H 2025.
• Report Topline Pivotal Phase 2 Data for Stiff Person Syndrome (SPS) in 1H 2026.
• BLA filing for Stiff Person Syndrome (SPS) in 1H 2026.

Key Dates

Keywords

KYV-101, KYV-102, Stiff Person Syndrome, Myasthenia Gravis, Lupus Nephritis, Autoimmune Diseases, CAR T-cell therapy, Clinical Trials, BLA Filing, FDA, Financial Results, Kyverna Therapeutics